Therapeutic nuclear medicine, also known as theranostics, combines tumour targeting with a therapeutic dose of radiation. Tumour targeting allows radiopharmaceuticals to selectively target cells associated with disease due to the affinity between the drug and certain receptors expressed by the relevant cells. The targeting molecule delivers a therapeutic dose of radiation to kill tumour cells. Blue Earth Diagnostics acquired exclusive, worldwide rights to radiohybrid Prostate Specific Membrane Antigen (rhPSMA) targeted technology in order to expand its oncology imaging and theranostics portfolio. The Company is investigating the use of rhPSMA (18F) as a diagnostic imaging agent for prostate cancer in addition to exploring promising therapeutic leads for treatment of the disease.